Clinical Trials on Cutaneous Melanoma in South Africa

Total 374 results

Array BioPharma

Terminated

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Locally Advanced Metastatic BRAF Mutant Melanoma

Australia, Canada, Netherlands, United States
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Metastatic Melanoma

United States, Australia
Genentech, Inc.

Completed

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Malignant Melanoma

United States, Australia
Lipotek Pty Ltd
Royal Adelaide Hospital; Trident Clinical Research Pty Ltd

Completed

Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma

Melanoma

Australia
Prisma Health-Upstate
Oncolix, Inc.

Terminated

Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Melanoma

United States
Trans Tasman Radiation Oncology Group
University Medical Center Groningen; Australian and New Zealand Intensive Care...

Completed

Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes

Lymph Node Disease | Malignant Melanoma

Australia, New Zealand, Netherlands, Brazil
Aura Biosciences

Terminated

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) (IL)

Choroidal Melanoma | Indeterminate Lesions

United States
Abbott
Biogen

Terminated

A Study of Volociximab in Metastatic Melanoma

Stage IV Melanoma

United States
Medical University of South Carolina

Terminated

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
Aura Biosciences

Active, not recruiting

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma

United States
Melanoma Institute Australia
Novartis

Recruiting

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

Melanoma

Australia
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

United States, Australia
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
CancerVax Corporation

Unknown

Vaccine Therapy in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States, Australia
Hoffmann-La Roche

Completed

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States
Provectus Pharmaceuticals

Completed

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Melanoma

Australia
QBiotics Group Limited

Terminated

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Melanoma

Australia
Melanoma and Skin Cancer Trials Limited
Trans Tasman Radiation Oncology Group

Active, not recruiting

Neurotropic Melanoma of the Head and Neck (RTN2)

Melanoma

United States, Australia, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
Viralytics

Completed

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) (PXS-X02)

Malignant Melanoma

Australia
National Cancer Institute (NCI)

Completed

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Melanoma (Skin)

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
AmpliMed Corporation

Completed

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Malignant Melanoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (Neo Trio)

Melanoma

Australia
Provectus Pharmaceuticals

Completed

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Melanoma

United States, Australia
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
Eisai Inc.
Quintiles, Inc.

Completed

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Stage IV Melanoma

United Kingdom, United States, Spain, Germany, Italy
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Melanoma

Australia, United States
AVAX Technologies

Terminated

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
Hoffmann-La Roche

Completed

A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma

Metastatic Melanoma

United States, Canada, Belgium, Spain, France, Russian Federation, Australia
Takeda

Completed

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Melanoma | Neoplasms

United States, Australia
Melanoma and Skin Cancer Trials Limited
University of Oxford; Trans Tasman Radiation Oncology Group

Active, not recruiting

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma (WBRTMel)

Metastatic Melanoma

Norway, Australia, United Kingdom
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
Aura Biosciences

Recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma | Indeterminate Lesions

United States, Australia, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States, Canada
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote-695)

Stage III/IV Melanoma

United States, Australia, Canada, Italy, Switzerland
Hoffmann-La Roche

Completed

A Study of RO5185426 in Patients With Metastatic Melanoma

Malignant Melanoma

United States
Novartis Pharmaceuticals

Terminated

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Uveal Melanoma

United States, Australia, France, Netherlands, Spain, Norway
Aura Biosciences

Recruiting

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Choroidal Melanoma | Indeterminate Lesions of Eye

United States
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Melanoma (Skin)

United States
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
Bristol-Myers Squibb
Medarex

Completed

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

France, United States, Australia, Belgium, Germany, South Africa, Canada, Brazil, Czech Republic, Hungary
Eisai Inc.

Completed

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Metastatic Melanoma

United States, Australia, United Kingdom, Germany
Melanoma Institute Australia

Active, not recruiting

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)

Melanoma

Australia

Clinical Trials on Cutaneous Melanoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations